Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.

Metabolomics, a global study of metabolites and small molecules, is a novel expanding field. In this pilot study, metabolomics has been applied to serum samples from women with metastatic breast cancer to explore outcomes and response to treatment.
Pre-treatment and serial on-treatment serum samples were available from an international clinical trial in which 579 women with metastatic breast cancer were randomized to paclitaxel plus either a targeted anti-HER2 treatment (lapatinib) or placebo. Serum metabolomic profiles were obtained using 600 MHz nuclear magnetic resonance spectroscopy. Profiles were compared with time to progression, overall survival and treatment toxicity.
Pre- and on-treatment serum samples were assessed for over 500 patients. Unbiased metabolomic profiles in the biologically unselected overall trial population did not correlate with outcome or toxicity. In a subgroup of patients with HER2-positive disease treated with paclitaxel plus lapatinib, metabolomic profiles from patients in the upper and lower thirds of the dataset showed significant differences for time to progression (N = 22, predictive accuracy = 89.6%) and overall survival (N = 16, predictive accuracy = 78.0%).
In metastatic breast cancer, metabolomics may play a role in sub selecting patients with HER2 positive disease with greater sensitivity to paclitaxel plus lapatinib.
AuthorsLeonardo Tenori, Catherine Oakman, Wederson M Claudino, Patrizia Bernini, Silvia Cappadona, Stefano Nepi, Laura Biganzoli, Michael C Arbushites, Claudio Luchinat, Ivano Bertini, Angelo Di Leo
JournalMolecular oncology (Mol Oncol) Vol. 6 Issue 4 Pg. 437-44 (Aug 2012) ISSN: 1878-0261 [Electronic] Netherlands
PMID22687601 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Quinazolines
  • lapatinib
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Paclitaxel
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Breast Neoplasms (blood, drug therapy, metabolism)
  • Clinical Trials, Phase III as Topic
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Metabolome
  • Metabolomics
  • Neoplasm Metastasis
  • Paclitaxel (therapeutic use)
  • Pilot Projects
  • Quinazolines (therapeutic use)
  • Randomized Controlled Trials as Topic
  • Receptor, ErbB-2 (metabolism)
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: